Cargando…
Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients
BACKGROUND: Treatment of HIV-infected patients with interleukin-2 (IL-2) produces significant increases in CD4 T cell counts; however an associated qualitative improvement in cells function has yet to be conclusively demonstrated. By measuring mycobacterial killing activity, we evaluated IL-2-mediat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993926/ https://www.ncbi.nlm.nih.gov/pubmed/21124762 http://dx.doi.org/10.1371/journal.pone.0014119 |
_version_ | 1782192860033974272 |
---|---|
author | Sabbatini, Francesca Bandera, Alessandra Ferrario, Giulio Trabattoni, Daria Marchetti, Giulia Franzetti, Fabio Clerici, Mario Gori, Andrea |
author_facet | Sabbatini, Francesca Bandera, Alessandra Ferrario, Giulio Trabattoni, Daria Marchetti, Giulia Franzetti, Fabio Clerici, Mario Gori, Andrea |
author_sort | Sabbatini, Francesca |
collection | PubMed |
description | BACKGROUND: Treatment of HIV-infected patients with interleukin-2 (IL-2) produces significant increases in CD4 T cell counts; however an associated qualitative improvement in cells function has yet to be conclusively demonstrated. By measuring mycobacterial killing activity, we evaluated IL-2-mediated functional immune enhancement ex vivo in immunological non-responders (INRs). METHODS AND FINDINGS: PBMC from 12 immunological non-responders (INRs) (CD4+<200/µl, HIV-RNA<50 cp/ml) on combination antiretroviral treatment (cART) were collected at baseline, and after 3 IL-2 cycles. Eight INRs receiving only cART were studied as controls. After 21 days of PBMC incubation with a virulent M. avium suspension, counts of residual colony forming units (CFUs) and concentrations of TNF-α, IL-10 and IFN-γ were determined. In IL-2 treated patients, a significant reduction in mean residual CFUs of PBMC cultures was observed (p<0.01). Moreover, following IL-2 treatment, significant increases in PBMC's IFNγ production (p = 0.02) and substantial reductions in IL-10 levels were observed. CONCLUSIONS: IL-2 therapy restores the ability of the lympho-monocyte system in eliciting an effective response against mycobacterial infections. Our data indicate the possibility of a clinical role held by IL-2 in enhancing the immune function of subjects unable to achieve immune competence through cART alone. |
format | Text |
id | pubmed-2993926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-29939262010-12-01 Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients Sabbatini, Francesca Bandera, Alessandra Ferrario, Giulio Trabattoni, Daria Marchetti, Giulia Franzetti, Fabio Clerici, Mario Gori, Andrea PLoS One Research Article BACKGROUND: Treatment of HIV-infected patients with interleukin-2 (IL-2) produces significant increases in CD4 T cell counts; however an associated qualitative improvement in cells function has yet to be conclusively demonstrated. By measuring mycobacterial killing activity, we evaluated IL-2-mediated functional immune enhancement ex vivo in immunological non-responders (INRs). METHODS AND FINDINGS: PBMC from 12 immunological non-responders (INRs) (CD4+<200/µl, HIV-RNA<50 cp/ml) on combination antiretroviral treatment (cART) were collected at baseline, and after 3 IL-2 cycles. Eight INRs receiving only cART were studied as controls. After 21 days of PBMC incubation with a virulent M. avium suspension, counts of residual colony forming units (CFUs) and concentrations of TNF-α, IL-10 and IFN-γ were determined. In IL-2 treated patients, a significant reduction in mean residual CFUs of PBMC cultures was observed (p<0.01). Moreover, following IL-2 treatment, significant increases in PBMC's IFNγ production (p = 0.02) and substantial reductions in IL-10 levels were observed. CONCLUSIONS: IL-2 therapy restores the ability of the lympho-monocyte system in eliciting an effective response against mycobacterial infections. Our data indicate the possibility of a clinical role held by IL-2 in enhancing the immune function of subjects unable to achieve immune competence through cART alone. Public Library of Science 2010-11-29 /pmc/articles/PMC2993926/ /pubmed/21124762 http://dx.doi.org/10.1371/journal.pone.0014119 Text en Sabbatini et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Sabbatini, Francesca Bandera, Alessandra Ferrario, Giulio Trabattoni, Daria Marchetti, Giulia Franzetti, Fabio Clerici, Mario Gori, Andrea Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients |
title | Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients |
title_full | Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients |
title_fullStr | Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients |
title_full_unstemmed | Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients |
title_short | Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients |
title_sort | qualitative immune modulation by interleukin-2 (il-2) adjuvant therapy in immunological non responder hiv-infected patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993926/ https://www.ncbi.nlm.nih.gov/pubmed/21124762 http://dx.doi.org/10.1371/journal.pone.0014119 |
work_keys_str_mv | AT sabbatinifrancesca qualitativeimmunemodulationbyinterleukin2il2adjuvanttherapyinimmunologicalnonresponderhivinfectedpatients AT banderaalessandra qualitativeimmunemodulationbyinterleukin2il2adjuvanttherapyinimmunologicalnonresponderhivinfectedpatients AT ferrariogiulio qualitativeimmunemodulationbyinterleukin2il2adjuvanttherapyinimmunologicalnonresponderhivinfectedpatients AT trabattonidaria qualitativeimmunemodulationbyinterleukin2il2adjuvanttherapyinimmunologicalnonresponderhivinfectedpatients AT marchettigiulia qualitativeimmunemodulationbyinterleukin2il2adjuvanttherapyinimmunologicalnonresponderhivinfectedpatients AT franzettifabio qualitativeimmunemodulationbyinterleukin2il2adjuvanttherapyinimmunologicalnonresponderhivinfectedpatients AT clericimario qualitativeimmunemodulationbyinterleukin2il2adjuvanttherapyinimmunologicalnonresponderhivinfectedpatients AT goriandrea qualitativeimmunemodulationbyinterleukin2il2adjuvanttherapyinimmunologicalnonresponderhivinfectedpatients |